Indeed, downregulation of DDX5 by ASO inhibited PCa cell proliferation and overcame CRPC resistance [27], supporting that DDX5 may represent a good therapeutic target for the treatment of aggressive PCa. Here, DDX5 is linked to posterior cortical atrophy.